Tarsus Pharmaceuticals, Inc.
Regulated industryPhysical productsDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $78.20
- 52-Week Range
- $53.89 – $91.53
- Market Cap
- $3.74B
- P/E (TTM)
- —
- EPS (TTM)
- -15.86
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 36.00
- PEG Ratio
- —
- Return on Equity
- -319.84%
- Return on Assets
- -7.88%
- Gross Margin
- 83.78%
- Operating Margin
- -9.61%
- Profit Margin
- -102.93%
- Current Ratio
- 1.96
- Debt/Equity
- 0.86
- Total Debt
- $89.43M
- Free Cash Flow
- $79.94M
- Revenue Growth
- 63.90%
- Earnings Growth
- —
- Enterprise Value
- $3.52B
Market Snapshot
About
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on applying proven chemistry to address unmet needs in ophthalmic disease. The company's lead product candidate treats Demodex blepharitis, a disease caused by mite infestation of eyelids. Tarsus is developing novel therapeutic approaches for eye and skin conditions.